Loading...
Loading...
MOR| Name | Value |
|---|---|
| Revenues | 59.4M |
| Cost of Revenue | 17.2M |
| Gross Profit | 42.2M |
| Operating Expense | 97.3M |
| Operating I/L | -55.1M |
| Other Income/Expense | -183.9M |
| Interest Income | 6.2M |
| Pretax | -239.0M |
| Income Tax Expense | -4.0M |
| Net Income/Loss | -235.0M |
MorphoSys AG is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutic antibodies for cancer and autoimmune diseases. Its flagship product, Tafasitamab, targets B cell malignancies. The company also develops Pelabresib for myelofibrosis, Felzartamab for anti-PLA2R-positive membranous nephropathy, and CPI-0209 for anti-tumor activity. Additionally, it has partnerships with pharmaceutical companies for the development of Gantenerumab for Alzheimer's disease, Otilimab for rheumatoid arthritis, Tremfya for psoriasis, and MOR210/TJ210 for immuno-oncology and autoimmune diseases.
